Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBH492 in relapsed/refractory CLL and NHL
NCT04240704Phase 1Terminated
- Sponsor
- Novartis
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of JBH492 in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 32 months, Adverse Events at 32 months and 4 more. Started Sep 2020; status: terminated.
02
Drugs
JBH492
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04240704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240704.